文献速递角膜与眼表疾病

培养人角膜内皮细胞注射治疗有晶状体眼大疱性角膜病变

Cultured Human Corneal Endothelial Cell Injection Therapy in Phakic Eyes with Bullous Keratopathy.
PubMed 文献 · Am J Ophthalmol · 2026-07-24

多中心回顾性干预病例系列纳入5例有晶状体眼大疱性角膜病变患者,接受培养人角膜内皮细胞注射治疗并随访6个月。结果显示最佳矫正视力logMAR从1.06±0.57改善至0.22±0.36,中央角膜厚度从782±104 µm降至578±61 µm,角膜透明度均改善且稳定,眼压无显著变化,无并发症及临床显著白内障进展。

要点

  • 有晶状体眼大疱性角膜病变患者接受cHCEC注射后视力与角膜厚度显著改善。
  • 术后6个月角膜透明度均改善且稳定,眼压无显著变化,未见并发症。
  • 随访期间未观察到临床显著的白内障进展,提示可能保留晶状体。

核心结论

  • 培养人角膜内皮细胞注射治疗在有晶状体眼大疱性角膜病变中显示出良好的短期临床结局,可能是一种有前景的保留晶状体治疗选择。

研究设计与样本

  • 多中心回顾性干预病例系列,纳入5例连续有晶状体眼大疱性角膜病变患者共5眼,接受cHCEC注射治疗并完成6个月随访。

主要发现

  • 所有眼角膜透明度改善并在6个月随访期间保持稳定。
  • 术前因严重角膜水肿无法测量内皮细胞密度,术后6个月内皮细胞密度范围为693至1622 cells/mm²。

临床怎么用

  • 对于有晶状体眼大疱性角膜病变且希望避免角膜内皮移植可能加速白内障进展风险的患者,cHCEC注射治疗可作为保留晶状体的潜在选择。

局限性

  • 样本量小(5眼)且为回顾性设计,随访仅6个月,需更大规模对照研究和更长随访验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the safety and efficacy of cultured human corneal endothelial cell (cHCEC) injection therapy in phakic eyes with bullous keratopathy (BK), for which endothelial keratoplasty may accelerate cataract progression due to intraoperative manipulation and postoperative gas tamponade. DESIGN: Multicenter retrospective interventional case series. PARTICIPANTS: Five consecutive phakic eyes of 5 patients with BK who underwent cHCEC injection therapy and completed 6 months of follow-up. MAIN OUTCOMES AND MEASURES: Best-corrected visual acuity (BCVA), central corneal thickness (CCT), endothelial cell density (ECD), intraocular pressure (IOP) and cataract progression. RESULTS: Mean logMAR best-corrected visual acuity (BCVA) improved from 1.06 ± 0.57 preoperatively to 0.22 ± 0.36 at 6 months (mean change, -0.84; 95% CI, -1.32 to - 0.36; p = .008). Mean central corneal thickness (CCT) decreased from 782 ± 104 µm to 578 ± 61 µm (mean change, -204 µm; 95% CI, -306 to - 102 µm; p = .005). Corneal clarity improved in all eyes and remained stable throughout the 6-month follow-up. Endothelial cell density (ECD) was not measurable preoperatively because of severe corneal edema. At 6 months, postoperative ECD ranged from 693 to 1622 cells/mm². Mean intraocular pressure (IOP) changed from 10.1 ± 4.3 mm Hg to 11.7 ± 3.1 mm Hg (mean change, 1.54 mm Hg; 95% CI, -4.39 to 7.47 mm Hg; p = .511). No intraoperative or postoperative complications, including cystoid macular edema, were observed. No clinically significant cataract progression was noted during follow-up. CONCLUSIONS: cHCEC injection therapy demonstrated favorable short-term clinical outcomes in phakic eyes with BK and may represent a promising lens-preserving treatment option. Larger controlled studies with longer follow-up are warranted.

来源:Am J Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Ogino R, Kobayashi A, Shirane M, et al. Cultured Human Corneal Endothelial Cell Injection Therapy in Phakic Eyes with Bullous Keratopathy. Am J Ophthalmol. 2026. PMID: 42498237. doi:10.1016/j.ajo.2026.07.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。